BioMarin Pharmaceutical Inc. акциялары

BioMarin Pharmaceutical Inc. operates as a leading biopharmaceutical firm, concentrating on the creation and worldwide commercialization of therapeutic interventions for critical, rare medical conditions and life-threatening diseases. Its market reach extends across the United States, Europe, Latin America, the Middle East, and the Asia Pacific region. The company's current portfolio features several key medications: VIMIZIM, an enzyme replacement therapy for mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder. VOXZOGO, a once-daily injectable analog of c-type natriuretic peptide (CNP), approved for achondroplasia. NAGLAZYME, a recombinant form of N-acetylgalactosamine 4-sulfatase, prescribed for patients with MPS VI. PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme, delivered subcutaneously to lower blood Phe levels. BRINEURA, a recombinant human tripeptidyl peptidase 1, indicated for ceroid lipofuscinosis type 2, a type of Batten disease. ALDURAZYME, a purified protein designed to replicate the naturally occurring human enzyme alpha-L-iduronidase. KUVAN, a proprietary synthetic oral variant of 6R-BH4, employed to manage phenylketonuria, an inherited metabolic illness. ROCTAVIAN, an adeno-associated virus (AAV) vector-based treatment for severe hemophilia A. Beyond its marketed products, BioMarin maintains an active development pipeline. This includes BMN 333, a longer-acting CNP aimed at various growth disorders like achondroplasia and hypochondroplasia; BMN 349, an experimental oral therapeutic for liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide under investigation for Duchenne muscular dystrophy. The company's distribution channels encompass specialty pharmacies, hospitals, non-U.S. government entities, distributors, and pharmaceutical wholesalers. BioMarin also holds licensing and collaborative agreements with partners such as Catalyst Pharmaceutical Partners, Inc. and Ares Trading S.A. Established in 1996, the company's corporate headquarters are located in San Rafael, California.